Potential Therapeutic Use of PPAR-Programed Human Monocyte-Derived Dendritic Cells in Cancer Vaccination Therapy
Figure 2
The molecular basis for the potential use of
PPAR-programed dendritic cells during tumor
vaccination.DC progenitors are differentiated
in the presence of PPAR agonists. A PPAR-programed DC showed increased CD1d
expression. In the presence of GalCer, the
treated DC is capable of
inducing iNKT cell expansion.
The adoptively transfered iNKTs can
induce activation of iDCs and IL-12 secretion in cancer patients. This can
lead to improved ability to kill tumor cells.
